On 27 August, China Medical System Holdings Limited (“CMS” or the “Group”) spent HK$14,679,240 to repurchase 1,000,000 shares of the company, representing 0.0405% of the issued shares. This share repurchase has firmly reflected the management’s strong confidence in the company’s operation, innovative R&D, and the development prospects of new businesses such as the dermatology and medical aesthetic business.
Given the deepened medical reform, the Group has been actively seeking breakthroughs and changes, and has efficiently acquired more than 20 innovative products with competitive differentiation advantages, 8 of which are expected to be launched in China in the next three years, empowering
the rapid development of the Group. Meanwhile, the Group has efficiently integrated its advantageous resources to constantly expand its business boundaries, and promoted the development of the new businesses, such as the dermatology and medical aesthetic business and the healthcare business, further
enhancing its comprehensive competitive strength, so as to build a more proactive and promising “New CMS” and continuously create more value for society, employees and shareholders!